胰高血糖素样肽-1受体激动剂为下丘脑性肥胖提示了新的治疗选择。
Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity.
作者信息
Ma Wanlu, Zhang Bo, Chen Xiaoping
机构信息
Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
出版信息
J Diabetes Investig. 2025 Mar;16(3):357-359. doi: 10.1111/jdi.14372. Epub 2024 Dec 11.
Abstract
We briefly summarizes the mechanism of GLP-1RA therapy in HO both in rodents and in humans. We also summarized the clinical trials and case reports of GLP-1RA therapy in HO, especially the more and more often used semaglutide. We are hoping the therapy of GLP-1RA in HO will arouse more attention from clinicians in the future.
摘要
我们简要总结了胰高血糖素样肽-1受体激动剂（GLP-1RA）在啮齿动物和人类中治疗异位骨化（HO）的机制。我们还总结了GLP-1RA治疗HO的临床试验和病例报告，尤其是越来越常用的司美格鲁肽。我们希望未来GLP-1RA在HO治疗方面能引起临床医生更多的关注。
Zotero 插件